Do atypical features affect outcome in depressed outpatients treated with citalopram?

International Journal of Neuropsychopharmacology

Volumn 13, Issue 1, 2010, Pages 15-30

  Stewart, Jonathan W ^a   McGrath, Patrick J ^a   Fava, Maurizio ^b   Wisniewski, Stephen R ^c   Zisook, Sidney ^d   Cook, Ian ^e   Nierenberg, Andrew A ^b   Trivedi, Madhukar H ^f   Balasubramani, G K ^c   Warden, Diane ^f   Lesser, Ira ^e   John Rush, A ^g  

^a Surgeons of Columbia University ^*  (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

Citalopram; Depression with atypical features; STARD

Indexed keywords

CITALOPRAM; LORAZEPAM; TRAZODONE;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DISEASE SEVERITY; DRUG ABUSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FEMALE; HELP SEEKING BEHAVIOR; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL DISEASE; MENTAL HEALTH CARE; ONSET AGE; OUTPATIENT; PHYSICAL DISEASE; PRIORITY JOURNAL; RATING SCALE; REMISSION; SIDE EFFECT; SOCIAL ASPECT; SUICIDAL IDEATION; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNEMPLOYMENT;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; ANXIETY; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SOCIOECONOMIC FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77949656934     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145709000182     Document Type: Article

References (65)

1. Amori G, Lenox RH (1989). Do volunteer subjects bias clinical trials? Journal of Clinical Psychopharmacology 9, 321-327.
2. Angst J, Gamma A, Benazzi F, Silverstein B, Ajdacic-Gross VA, Eich D, Rössler W (2006). Atypical depressive syndromes in varying definitions. European Archives of Psychiatry and Clinical Neuroscience 257, 44-54.
3. Angst J, Gamma A, Sellaro R, Zhang H, Merikangas K (2002). Toward validation of atypical depression in the community: results of the Zurich cohort study. Journal of Affective Disorders 72, 125-138.
4. Anisman H, Ravindran AV, Griffiths J, Merali Z (1999). Endocrine and cytokine correlates of major depression and dysthymia with and without atypical features. Molecular Psychiatry 4, 182-188.
5. APA (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn, Washington, DC: American Psychiatric Association.
6. Asnis GM, McGinn LK, Sanderson WC (1995). Atypical depression: clinical aspects and noradrenergic function. American Journal of Psychiatry 152, 31-36.
7. Benazzi F (1999). Prevalence and clinical features of atypical depression in depressed outpatients: a 467-case study. Psychiatry Research 86, 259-264.
8. Benazzi F (2002). Psychomotor changes in melancholic and atypical depression: unipolar and bipolar-II subtypes. Psychiatry Research 112, 211-220.
9. Bielski RJ, Lydiard RB (1997). Therapeutic trial participants: where do we find them and what does it cost? Psychopharmacology Bulletin 33, 75-78.
10. Brown WA, Johnson MF, Chen MG (1992). Clinical features of depressed patients who do and do not improve with placebo. Psychiatry Research 41, 203-214.
11. Corey-Lisle PK, Nash R, Stang P (2004). Swindle R. Response, partial response, and nonresponse in primary care treatment of depression. Archives of Internal Medicine 164, 1197-1204.
12. Davidson JR, Miller RD, Turnbull CD, Sullivan JL (1982). Atypical depression. Archives of General Psychiatry 39, 527-534.
13. Fava M, Alpert JE, Carmin CN, Wisniewski SR, Trivedi MH, Biggs MM, Shores-Wilson K, Morgan D, Schwartz T, Balasubrmanai GK, Rush AJ (2004). Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychological Medicine 34, 1299-1308.
14. Fava M, Rush AJ, Trivedi MH, Nierenberg AA, Thase ME, Sackeim HA, Quitkin FM, Wisniewski S, Lavori PW, Rosenbaum JF, Kupfer DJ (2003). Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatric Clinics of North America 26, 457-494.
15. Hamilton M (1967). Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology 6, 278-296.
16. Himmelhoch JM, Thase ME, Mallinger AG, Houck P (1991). Tranylcypromine versus imipramine in anergic bipolar depression. American Journal of Psychiatry 148, 910-916.
17. Horwath E, Johnson J, Weissman MM, Hornig CD (1992). The validity of major depression with atypical features based on a community study. Journal of Affective Disorders 26, 117-126.
18. Joyce PR, Mulder RT, Luty SE, Sullivan PF, McKenzie JM, Abbott RM, Stevens IF (2002). Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline. Australian and New Zealand Journal of Psychiatry 36, 384-391.
19. Kendel V, Mergl R, Coyne JC, Kohnen R, Allgaier A-K, Rühl E, Möller H-J, Hegerl U (2004). Depression with atypical features in a sample of primary care outpatients: prevalence, specific characteristics and consequences. Journal of Affective Disorders 83, 237-242.
20. Kendler KS, Eaves LJ, Walters EE, Neale MC, Heath AC, Kessler RC (1996). The identification and validation of distinct depressive syndromes in a population-based sample of female twins. Archives of General Psychiatry 53, 391-399.
21. Khan AY, Carrithers J, Preskorn SH, Lear R, Wisniewski SR, Rush AJ, Stegman D, Kelley C, Kreiner K, Nierenberg AA, Fava M (2006). Clinical and demographic factors associated with DSM-IV melancholic depression. Annals of Clinical Psychiatry 18, 91-98.
22. Klein DF (1989). The pharmacological validation of psychiatric diagnosis. In: Robins L, Barrett J (Eds.), Validity of Psyhciatric Diagnosis (pp. 203-216). New York: Raven Press.
23. Levitan RD, Lesage A, Parikh SV, Goering P, Kennedy SH (1997). Reversed neurovegetative symptoms of depression: a community study or Ontario. American Journal of Psychiatry 154, 934-940.
24. Liebowitz MR, Quitkin FM, Stewart JW, McGrath PJ, Harrison WM, Markowitz JS, Rabkin JG, Tricamo E, Goetz DM, Klein DF (1988). Antidepressant specificity in atypical depression. Archives of General Psychiatry 45, 129-137.
25. Linn BS, Linn MW, Gurel L (1968). Cumulative Illness Rating Scale. Journal of the American Geriatric Society 16, 622-626.
26. Lonnqvist J, Sihvo S, Syvalahti E, Kiviruusu O (1994). Moclobemide and fluoxetine in atypical depression: a double-blind trial. Journal of Affective Disorders 32, 169-177.
27. Matza LS, Revicki DA, Davidson JR, Stewart JW (2003). Depression with atypical features in the National Comorbidity Survey: classification, description, and consequences. Archives of General Psychiatry 60, 817-826.
28. McGrath PJ, Stewart JW, Janal MN, Petkova E, Quitkin FM, Klein DF (2000). A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression. American Journal of Psychiatry 157, 344-350.
29. McGrath PJ, Stewart JW, Quitkin FM, Chen Y, Alpert JE, Nierenberg AA, Fava M, Cheng J, Petkova E (2006). Predictors of relapse in a prospective study of fluoxetine treatment of major depression. American Journal of Psychiatry 163, 1542-1548.
30. Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai AH, Mulsant B, Reynolds III CF (1992). Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Research 41, 237-248.
31. Novick JS, Stewart JW, Wisniewski SR, Cook IA, Manev R, Nierenberg AA, Rosenbaum JF, Shores-Wilson K, Balasubramani GK, Biggs MM, Zisook S, Rush AJ; STAR*D investigators (2005). Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR*D. Journal of Clinical Psychiatry 66, 1002-1011.
32. Pande AC, Birkett M, Fechner-Bates S, Haskett RF, Greden JF (1996). Fluoxetine versus phenelzine in atypical depression. Biological Psychiatry 40, 1017-1020.
33. Parker G, Blignault I (1983). A comparative study of neurotic depression in symptomatic volunteers. Australia and New Zealand Journal of Psychiatry 17, 74-81.
34. Parker G, Roy K, Mitchell P, Wilhelm K, Malhi G, Hadzi-Pavlovic D (2002). Atypical depression: a reappraisal. American Journal of Psychiatry 159, 1470-1479.
35. Paykel ES, Hollyman JA, Freeling P, Sedgwick P (1988). Predictors of therapeutic benefit from amitriptyline in mild depression: a general practice placebo-controlled trial. Journal of Affective Disorders 14, 83-95.
36. Perugi G, Akiskal HS, Lattanzi L, Cecconi D, Mastrocinque C, Patronelli A, Vignoli S, Bemi E (1998). The high prevalence of 'soft' bipolar (II) features in atypical depression. Comprehensive Psychiatry 39, 63-71.
37. Posternak MA, Zimmerman M (2002). Partial validation of the atypical features subtype of major depressive disorder. Archives of General Psychiatry 59, 70-76.
38. Quitkin FM, McGrath PJ, Stewart JW, Harrison W, Tricamo E, Wager SG, Ocepek-Welikson K, Nunes E, Rabkin JG, Klein DF (1990). Atypical depression, panic attacks, and response to imipramine and phenelzine. A replication. Archives of General Psychiatry 47, 935-941.
39. Rabkin JG, Stewart JW, Quitkin FM, McGrath PJ, Harrison WM, Klein DF (1996). Should atypical depression be included in DSM-IV? In: Widiger TA, Frances AJ, Pincus HA, Ross R, First MB, Davis WW (Eds.), APA DSM-IV Source Book (pp. 239-260). Washington, DC: American Psychiatric Association.
40. Rapaport MH, Frevert T, Babior S, Seymour S, Zisook S, Kelsoe J, Judd LL (1996). A comparison of descriptive variables for clinical patients and symptomatic volunteers with depressive disorders. Journal of Clinical Psychopharmacology 16, 242-246.
41. Robins E, Guze SB (1970). Establishment of diagnostic validity in psychiatric illness: its application to schizophrenia. American Journal of Psychiatry 126, 983-987.
42. Rush AJ, Carmody TJ, Ibrahim HM, Trivedi MH, Biggs MM, Shores-Wilson K, Crismon ML, Toprac MG, Kashner TM (2006). Comparison of self-report and clinician ratings on two inventories of depressive symptomatology. Psychiatric Services 57, 829-837.
43. Rush, AJ, Fava, M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA, Thase ME, Nierenberg AA, Quitkin FM, Kashner TM, et al.: Sequenced Treatment Alternatives to Relieve Depression (STAR*D) (2004). Rationale and design. Controlled Clinical Trials 25, 118-141.
44. Rush AJ, Giles DE, Schlesser MA, Fulton CL, Weissenburger J, Burns C (1986). The Inventory for Depressive Symptomatology (IDS): preliminary findings. Psychiatry Research 18, 65-87.
45. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH (1996). The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychological Medicine 26, 477-486.
46. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R, et al. (2003). The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biological Psychiatry 54, 573-585.
47. SmithD, DempsterC, GlanvilleJ, FreemantleN, Anderson I (2002). Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. British Journal of Psychiatry 180, 396-404.
48. Søgaard J, Lane R, Latimer P, Behnke K, Christiansen PE, Nielsen B, Ravindran AV, Reesal RT, Goodwin DP (1999). A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression. Journal of Psychopharmacology 13, 406-414.
49. Stewart JW, McGrath PJ, Quitkin FM, Klein DF (2007). Atypical depression: Current status and relevance to melancholia. Acta Psychiatrica Scandanavia 115 (Suppl. 433), 58-71.
50. Stewart JW, McGrath PJ, Quitkin FM, Klein DF (in press). DSM-IV depression with atypical features: is it valid? Neuropsychopharmacology.
51. Stewart JW, McGrath PJ, Rabkin JG, Quitkin FM (1993). Atypical depression: a valid clinical entity? Psychiatric Clinics of North America 16, 479-495.
52. Stewart JW, Quitkin FM, Liebowitz MR, McGrath PJ, Harrison WM, Klein DF (1983). Efficacy of desipramine in depressed outpatients. Response according to research diagnosis criteria diagnoses and severity of illness. Archives of General Psychiatry 40, 202-207.
53. Stewart JW, Quitkin FM, McGrath PJ, Amsterdam J, Fava M, Fawcett J, Reimherr F, Rosenbaum J, Beasley C, Roback P (1998). Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo. Archives of General Psychiatry 55, 334-343.
54. Stratta P, Bolino F, Cupillari M, Casacchia M (1991). A double-blind parallel study comparing fluoxetine with imipramine in the treatment of atypical depression. International Clinical Psychopharmacology 6, 193-196.
55. Sullivan PF, Kessler RC, Kendler KS (1998). Latent class analysis of lifetime depressive symptoms in the National Comorbidity Survey. American Journal of Psychiatry 155, 1398-1406.
56. Tedlow J, Fava M, Uebelacker L, Nierenberg AA, Alpert JE, Rosenbaum J (1998). Outcome definitions and predictors in depression. Psychotherapy & Psychosomatics 67, 266-270.
57. Thase ME, Entsuah AR, Rudolph RL (2001). Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. British Journal of Psychiatry 178, 234-241.
58. Thase ME, Last CG, Hersen M, Bellack AS, Himmelhoch JM (1984). Symptomatic volunteers in depression research: a closer look. Psychiatry Research 11, 25-33.
59. Trivedi MH, Rush AJ, Ibrahim HM, Carmody TJ, Biggs MM, Suppes T, Crismon ML, Shores-Wilson K, Toprac MG, Dennehy EB, Witte B, Kashner TM (2004). The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychological Medicine 34, 73-82.
60. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, et al.; STAR*D Study Team (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. American Journal of Psychiatry 163, 28-40.
61. Wilcox CS, Cohn JB, Linden RD, Heiser JF, Lucas PB, Morgan DL, DeFrancisco D (1992). Predictors of placebo response: a retrospective analysis. Psychopharmacology Bulletin 28, 157-162.
62. Wisniewski SR, Rush AJ, Balasubramani GK, Trivedi MH, Nierenberg AA (2006). Self-rated global measure of the frequency, intensity, and burden of side effects. Journal of Psychiatric Practice 12, 71-79.
63. Zimmerman M, Chelminski I, Posternak MA (2005). Generalizability of antidepressant efficacy trials: differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trial. American Journal of Psychiatry 162, 1370-1372.
64. Zimmerman M, Mattia JI (2001a). A self-report scale to help make psychiatric diagnoses: the Psychiatric Diagnostic Screening Questionnaire. Archives of General Psychiatry 58, 787-794.
65. Zimmerman M, Mattia JI (2001b). The Psychiatric Diagnostic Screening Questionnaire: development, reliability and validity. Comprehensive Psychiatry 42, 175-189.